Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jan;104(1):9-12.
doi: 10.3324/haematol.2018.206359.

Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia

Candida Vitale  1 , Alessandra Ferrajoli  2
Affiliations
Editorial

Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia

Candida Vitale et al. Haematologica. 2019 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Mechanisms of action of lenalidomide. The mechanisms of action of lenalidomide include: (A) direct effects on CLL cells and (B, C) modification of tumor-microenvironment interactions. This figure is reproduced with permission from Mattei R et al., Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 206;97:291–302. NLCs: nurse-like cells; EC: endothelial cells.
See this image and copyright information in PMC

Comment on

References

    1. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24(34):5343–5349. - PubMed
    1. Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118(13):3489–3498. - PMC - PubMed
    1. Kater AP, van Oers MHJ, van Norden Y, et al. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. Haematologica. 2019;104 (1):147–154. - PMC - PubMed
    1. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26(15):2519–2525. - PMC - PubMed
    1. Chen CI, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol. 2011;29(9):1175–1181. - PMC - PubMed